GT20029 IND Was Accepted by NMPA

(Summary description)

GT20029 IND Was Accepted by NMPA

(Summary description)

Information
Kintor annouced top-up placement to raise USD 150mn
Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19
Kintor Has Expanded Its Geographical Presence to Zhuhai
GT20029 IND Was Accepted by NMPA
Kintor and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing
Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA
Clinical Trial of Proxalutamide’s Trial of Hospitalized Covid-19 Patients Was Approved in Brazil

Scan the QR code to read on your phone